AKBA FY2025 SEC EDGAR DEF 14A #124 of 168 in industry

Akebia Therapeutics, Inc. CEO pay ratio

The CEO earned $5.7M in FY2025 against median worker pay of $270,410 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#124/168

Data updated August 2026

Subscribe to Akebia Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
21:1
Below Average (Scale: 0–1000:1)
CEO pay
$5.7M
Median worker
$270,410

Answer first

Akebia Therapeutics, Inc.'s FY2025 CEO total of $5.7M ranks #874 of 1,423 complete filings; its 21:1 pay ratio ranks #1204. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $270,410. Industry placement uses the FY2025 SIC-28 peer cohort (# 124 of 168, 27th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#874
$5.7M of 1,423 FY2025
Ratio rank
#1204
21:1 of 1,423
Industry pct
27th
below the industry median pay ratio

How Akebia Therapeutics, Inc. ranks nationally

Akebia Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$5,652,339 39th percentile higher than 39% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Akebia Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($5.7M) against pay ratio (21:1) for Akebia Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02253862.04507724.16761586.19015448.217.9:124.2:130.5:136.8:143.1:1CEO total payPay ratio (CEO : median worker)Akebia Therapeutics, Inc., CEO total pay: 5652339 · Pay ratio (CEO : median worker): 21:1Akebia Therapeutics, Inc.Kymera Therapeutics, Inc., CEO total pay: 8601747 · Pay ratio (CEO : median worker): 21:1Kymera Therapeutics, Inc.Nuvalent, Inc., CEO total pay: 540474 · Pay ratio (CEO : median worker): 21:1Nuvalent, Inc.Arvinas, Inc., CEO total pay: 327724 · Pay ratio (CEO : median worker): 20:1Arvinas, Inc.Kronos Worldwide Inc, CEO total pay: 2256576 · Pay ratio (CEO : median worker): 23:1Kronos Worldwide IncSyndax Pharmaceuticals Inc, CEO total pay: 7281788 · Pay ratio (CEO : median worker): 19:1Syndax Pharmaceuticals Inc
Akebia Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Akebia Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Akebia Therapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
21:1
FY2025
vs prior FY
+4:1
from FY2024 17:1
CEO $ YoY
+33%
$5.7M latest
Filings shown
5
FY2021–2025
Akebia Therapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $3.1M - $208,238 15:1 -
2022 $3.0M -3.1% $234,717 13:1 -2:1
2023 $2.8M -8.6% $234,062 12:1 -1:1
2024 $4.3M +54% $248,328 17:1 +5:1
2025 $5.7M +33% $270,410 21:1 +4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1517022, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
21:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$5.7M
Companies in Industry
168
vs. Industry Median
Below
#124 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Akebia Therapeutics, Inc.: near-parity Item 402(u) ratio

Akebia Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #124 of 168 Chemicals & Pharmaceuticals filers (27th percentile). the CEO earned 21× the median employee ($270,410) in FY2025.

At $270,410 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.

CEO Total Pay

$5.7M

FY2025 Summary Compensation, below median

Pay Ratio

21:1

Below typical

Akebia Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Akebia Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #124 of 168 Chemicals & Pharmaceuticals filers (27th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Akebia Therapeutics, Inc.'s $5.7M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #874 and ratio rank #1204 split - treat 21:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$5.7M
Median Employee Pay
$270,410
Pay Ratio
21:1
Filing Date
2026-04-28

Company Info

Ticker
AKBA
CIK
1517022
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1517022, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Akebia Therapeutics, Inc.'s FY2025 ratio 21:1 ranks #124 of 168 Chemicals & Pharmaceuticals filers (27th percentile).

Read with Akebia Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MID$ · ELITE-MED.

AdvanSix Inc. · MID$

ABS(ceo_total_comp) peer at $5.6M (Δ $5K lighter vs Akebia Therapeutics, Inc.); MODEST · HIGH-MED vs this page's FLOOR · MID$ · ELITE-MED.
Primerica, Inc. · MID$

ABS(ceo_total_comp) peer at $5.6M (Δ $20K lighter vs Akebia Therapeutics, Inc.); MID · PAR-MED vs this page's FLOOR · MID$ · ELITE-MED.
Unisys Corp · MID$

ABS(ceo_total_comp) peer at $5.6M (Δ $26K lighter vs Akebia Therapeutics, Inc.); STEEP · LOW-MED vs this page's FLOOR · MID$ · ELITE-MED.
Popular, Inc. · MID$

ABS(ceo_total_comp) peer at $5.7M (Δ $28K heavier vs Akebia Therapeutics, Inc.); MID · PAR-MED vs this page's FLOOR · MID$ · ELITE-MED.
Kymera Therapeutics, Inc. (SIC 28 pole)

Kymera Therapeutics, Inc. stamps FLOOR · HEAVY nearest in-SIC by ABS(pay_ratio) to Akebia Therapeutics, Inc.'s FLOOR filing.
National dual ranks · #874/#1204

Akebia Therapeutics, Inc.'s FY2025 package sits #874 by CEO dollars and #1204 by ratio under MID$ · FLOOR.
Ratio primer · FLOOR

Akebia Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Akebia Therapeutics, Inc. (CIK 1517022), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.